Phenylethylmalonamide serum levels in patients treated with primidone and the effects of other antiepileptic drugs.
Data are presented for the serum levels of 2-ethyl-2-phenylmalonamide (PEMA) in patients receiving anticonvulsant medication. Statistical analysis of these data indicates that the serum level of PEMA, which is a metabolite of primidone, is affected not only by the dose of primidone but also by the serum levels of other prescribed anticonvulsant drugs. In particular, phenobarbitone is shown to be a major perturbation upon the PEMA serum level.
D000927:Anticonvulsants / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D002220:Carbamazepine / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D008314:Malonates / Q000097:blood*; D010634:Phenobarbital / Q000494:pharmacology; D010657:Phenylethylmalonamide / Q000097:blood*; D010672:Phenytoin / Q000494:pharmacology; D011324:Primidone / Q000378:metabolism* / Q000627:therapeutic use; D014635:Valproic Acid / Q000494:pharmacology
D000927:Anticonvulsants; D008314:Malonates; D011324:Primidone; D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin; D010657:Phenylethylmalonamide; D010634:Phenobarbital